Halozyme Therapeutics (HALO) Tops Q2 EPS by 11c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $113.83 -1.13%
EPS Growth %: +30.8%
Financial Fact:
Interest and other income, net: 334K
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: +30.8%
Financial Fact:
Interest and other income, net: 334K
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.02, $0.11 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $43.4 million versus the consensus estimate of $25.12 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- Top Wealth Group expects net profit to double in fiscal 2026
- Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
